TLDR
- Soligenix’s stock drops as FLASH2 trial faces futility halt
- HyBryte setback forces Soligenix to review rare disease pipeline
- Soligenix weighs cash position after CTCL drug trial blow
- FLASH2 trial outcome puts HyBryte approval path under pressure
- Soligenix reviews options after Phase 3 CTCL study setback
Soligenix, Inc. (SNGX) stock traded at $0.45, down 0.68%, after the company reported a major Phase 3 setback. The Data Monitoring Committee recommended halting the FLASH2 trial for futility after an interim efficacy review. The update placed HyBryte’s development path and Soligenix’s strategic options back in focus.
FLASH2 Setback Pressures HyBryte Program
Soligenix said the FLASH2 trial tested HyBryte in patients with cutaneous T-cell lymphoma. The pivotal study evaluated synthetic hypericin after 18 weeks of continuous treatment. The interim review did not show the expected efficacy signal.
The company had built FLASH2 as a confirmatory study after earlier positive Phase 3 data. The first FLASH trial showed statistically significant lesion reductions after six weeks of treatment. Yet, the longer treatment design in FLASH2 did not repeat that signal.
Soligenix now plans to review the full dataset over the coming weeks. The company wants to understand why the study missed expectations. Besides, it may examine whether any patient subgroups showed a possible benefit.
Earlier FLASH data offered supportive background.
HyBryte uses synthetic hypericin with visible light activation to treat skin lesions. The treatment aims to avoid ultraviolet exposure linked with some current therapies. Soligenix has positioned HyBryte as a potentially safer option for CTCL patients.
The earlier Phase 3 FLASH trial enrolled 169 patients, with 166 evaluable participants. In its first cycle, 16% of HyBryte patients achieved at least 50% lesion reduction. By comparison, 4% of placebo patients reached that response level.
The open-label treatment cycles later showed higher response rates with longer exposure. Soligenix reported a 40% response rate after 12 weeks in one treatment group. Patients treated across three cycles showed a 49% positive response rate.
Company Reviews Cash, Pipeline and Strategic Options
Soligenix ended the update with about $5.9 million in cash. The company said it will evaluate all strategic options after the FLASH2 outcome. These options may include merger activity, asset reviews, and pipeline prioritisation.
The company also pointed to dusquetide as a possible development path. Dusquetide previously showed biological efficacy in a phase 2 study for Behçet’s disease. The candidate has received orphan drug designation from the European Medicines Agency.
Soligenix still operates a broader rare disease and public health pipeline. Its programmes include synthetic hypericin for psoriasis and vaccine candidates for ricin, Ebola, Marburg, and COVID-19. However, the FLASH2 setback now creates a near-term reset for its lead commercial plan.
CTCL Market Context Shapes the Next Step
Cutaneous T-cell lymphoma is a rare form of non-Hodgkin’s lymphoma. It develops when malignant T-cells migrate to the skin and form lesions. These lesions often begin as patches and then may progress into plaques and tumours.
The disease has no known cure, and lesions often return after treatment. Soligenix said CTCL affects about 31,000 people in the United States. It also estimates about 38,000 affected patients across Europe.
Regulators previously required a second successful Phase 3 trial to support HyBryte approval. That requirement made FLASH2 central to the product’s regulatory path. Soligenix must now decide whether further analysis can support any next step.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
